In silico Drug Discovery and Development: Benzene Mapping
•
1 like•674 views
This document discusses in silico drug discovery and development work done by Group A. They used structure-based drug design methods like pharmacophore modeling and FTMap benzene probe mapping to identify optimal drug targets. Specifically, they analyzed the HIV-1 protease protein target using PyMOL and FTMap to map benzene probes and identify four clusters of binding regions that could be used to develop potential drugs through pharmacophore modeling and screening of chemical probes.
Report
Share
Report
Share
Recommended
Biomarkers
The Journal of Biomarkers in Drug Development (JBDD) promotes rigorous research that makes a significant contribution in advancing knowledge for Biomarkers in Drug Development. JBDD includes all major themes pertaining to Biomarkers used in Drug Development.
US Medical Research And Dvt
The pharmaceutical industry invests heavily in research and development, with biopharmaceutical companies spending $65.2 billion annually on R&D. Developing a new drug takes an average of 10-15 years and costs $2.6 billion. Only about 20% of experimental drugs make it through clinical trials to receive FDA approval. After approval, many drugs fail to become commercial successes. However, post-approval research on existing drugs often leads to new uses that provide important medical advances. The industry and government play complementary roles in supporting medical research.
Market impact of WHO selection and prequalification of priority medicines
Presentation with the occasion of the Technical Briefing at World Halth Assembly, Geneva, 18 May 2011
Presentation1
Off-label drug use refers to when a drug is used in a way that is different from its FDA-approved label, such as being given in a different dose or route, or used to treat a different disease. While doctors can legally prescribe drugs off-label, drug companies cannot market drugs for off-label uses. Off-label drug use is common in cancer treatment because some cancer drugs work against many tumor types and cancer treatment is constantly evolving. When considering off-label drug treatment, patients should ask about the evidence and risks/benefits compared to approved drugs. The FDA could better regulate off-label use by systematically collecting post-market data on harms and benefits and disseminating reports on off-label evidence
Generic drug ppt
The document discusses the generic drug development process and the Hatch-Waxman Act. It defines generic drugs as being identical to brand name drugs in active ingredients, dosage form, quality and therapeutic effects. The generic drug approval process involves submitting an Abbreviated New Drug Application to the FDA that demonstrates bioequivalence to the brand name drug. The Hatch-Waxman Act established the modern system of generic drug regulation, providing incentives for generic drugs to gain FDA approval and compensating brand name drugs for patent time lost during regulatory review.
NDA/BLA/PMA and 510(k)
This document discusses various FDA approval pathways for drugs, biologics, and medical devices. It describes the New Drug Application (NDA) process for drug approval, the Biologics License Application (BLA) process for biologics approval, the Premarket Approval (PMA) process for high-risk Class III medical devices, and the 510(k) process for clearance of lower-risk Class I and II medical devices. The key FDA regulations and goals of demonstrating safety and effectiveness for intended uses are also summarized.
Biologics market
The Biologics Market was worth USD 267.58 billion in 2014 and is expected to reach approximately USD 373.66 billion by 2023, while registering itself at a compound annual growth rate (CAGR) of 3.78% during the forecast period. Biologics are medicates as hereditarily built proteins, got from human qualities. According to the US FDA, biologics can be made out of sugars, proteins, or nucleic acids or complex blends of these substances, or might live elements, for example, cells and tissues. The biologic medications are taken from an assortment of regular sources, for example, people, creatures, or microorganisms and comprise of items, for example, antibodies, blood and blood parts, allergenic, substantial cells, quality treatment, tissues, and recombinant remedial proteins. Propelled biotechnology strategies and complex procedures are utilized to produce biologics. They are at the cutting edge of biomedical research.
Pharmaceutical and Medical Device Development
This document summarizes the key steps in pharmaceutical and medical device development and regulatory approval processes. It discusses target identification, drug discovery methods, clinical trials, FDA approval pathways, post-marketing surveillance, and efforts to improve medical device safety. It also analyzes the comparative processes and a case study on Vioxx. The development timelines can take over 10 years and involve extensive testing and regulatory oversight by the FDA to ensure public safety.
Recommended
Biomarkers
The Journal of Biomarkers in Drug Development (JBDD) promotes rigorous research that makes a significant contribution in advancing knowledge for Biomarkers in Drug Development. JBDD includes all major themes pertaining to Biomarkers used in Drug Development.
US Medical Research And Dvt
The pharmaceutical industry invests heavily in research and development, with biopharmaceutical companies spending $65.2 billion annually on R&D. Developing a new drug takes an average of 10-15 years and costs $2.6 billion. Only about 20% of experimental drugs make it through clinical trials to receive FDA approval. After approval, many drugs fail to become commercial successes. However, post-approval research on existing drugs often leads to new uses that provide important medical advances. The industry and government play complementary roles in supporting medical research.
Market impact of WHO selection and prequalification of priority medicines
Presentation with the occasion of the Technical Briefing at World Halth Assembly, Geneva, 18 May 2011
Presentation1
Off-label drug use refers to when a drug is used in a way that is different from its FDA-approved label, such as being given in a different dose or route, or used to treat a different disease. While doctors can legally prescribe drugs off-label, drug companies cannot market drugs for off-label uses. Off-label drug use is common in cancer treatment because some cancer drugs work against many tumor types and cancer treatment is constantly evolving. When considering off-label drug treatment, patients should ask about the evidence and risks/benefits compared to approved drugs. The FDA could better regulate off-label use by systematically collecting post-market data on harms and benefits and disseminating reports on off-label evidence
Generic drug ppt
The document discusses the generic drug development process and the Hatch-Waxman Act. It defines generic drugs as being identical to brand name drugs in active ingredients, dosage form, quality and therapeutic effects. The generic drug approval process involves submitting an Abbreviated New Drug Application to the FDA that demonstrates bioequivalence to the brand name drug. The Hatch-Waxman Act established the modern system of generic drug regulation, providing incentives for generic drugs to gain FDA approval and compensating brand name drugs for patent time lost during regulatory review.
NDA/BLA/PMA and 510(k)
This document discusses various FDA approval pathways for drugs, biologics, and medical devices. It describes the New Drug Application (NDA) process for drug approval, the Biologics License Application (BLA) process for biologics approval, the Premarket Approval (PMA) process for high-risk Class III medical devices, and the 510(k) process for clearance of lower-risk Class I and II medical devices. The key FDA regulations and goals of demonstrating safety and effectiveness for intended uses are also summarized.
Biologics market
The Biologics Market was worth USD 267.58 billion in 2014 and is expected to reach approximately USD 373.66 billion by 2023, while registering itself at a compound annual growth rate (CAGR) of 3.78% during the forecast period. Biologics are medicates as hereditarily built proteins, got from human qualities. According to the US FDA, biologics can be made out of sugars, proteins, or nucleic acids or complex blends of these substances, or might live elements, for example, cells and tissues. The biologic medications are taken from an assortment of regular sources, for example, people, creatures, or microorganisms and comprise of items, for example, antibodies, blood and blood parts, allergenic, substantial cells, quality treatment, tissues, and recombinant remedial proteins. Propelled biotechnology strategies and complex procedures are utilized to produce biologics. They are at the cutting edge of biomedical research.
Pharmaceutical and Medical Device Development
This document summarizes the key steps in pharmaceutical and medical device development and regulatory approval processes. It discusses target identification, drug discovery methods, clinical trials, FDA approval pathways, post-marketing surveillance, and efforts to improve medical device safety. It also analyzes the comparative processes and a case study on Vioxx. The development timelines can take over 10 years and involve extensive testing and regulatory oversight by the FDA to ensure public safety.
Update on U.S. Regulation of Biosimilars
This document summarizes key issues regarding U.S. regulation of biosimilars, including the filing of the first biosimilar applications, requirements for demonstrating interchangeability, state substitution laws, challenges around naming conventions, and arguments on both sides of the naming debate. Industry is pursuing clinical trial designs aimed at demonstrating interchangeability, while FDA guidance is pending and naming remains controversial with pros arguing it ensures traceability and cons arguing it reduces biosimilar uptake.
Biosimilar Drugs: Overview and Regulatory Issues
This document provides an overview of biosimilar drugs and regulatory issues from a presentation given by Phil Johnson. It defines biosimilars and the FDA approval pathways for biologics and biosimilars. The FDA process for demonstrating biosimilarity is described, focusing on analytical, functional, and clinical data requirements. Issues around naming, interchangeability, and state-level legislation regarding substitution are discussed. Finally, the potential financial impact of biosimilars on the healthcare system is noted given rising drug costs and the patent cliff facing many biologic drugs.
Biosimilars-emerging market in india
Hi all, with the rigorous secondary research for almost one month helped me to understand basic things about biosimilars and made me do this presentation. Hope u will appreciate it while going through it. thanks.
If anyone in need of this presentation, pls.put ur emial ID in comment box. will be sharing. and please share your thoughts about the presentation. i will be more thankful.
U.S. Regulation of Biosimilars
Presentation at the Biosimilars and Follow-On Biologics 2014 Americas Conference, sponsored by Paradigm Global Events, February 12, 2014. Presentation focused on:
•Interchangeability
•State Substitution Laws
•Naming
•Risk Evaluation & Mitigation Strategies (REMS) and Their Impact on Biosimilars
•Where FDA Stands on Biosimilars
CHALLENGES TO GENERIC DRUG APPROVALS
Presentation to the IBC 9th Annual Conference on Generic Drugs, September 1999, in Washington, D.C., with an emphasis on reviewing how brand name drug companies have tried to challenge the approval of generic versions of their drug products.
Biosimilar - a mAb case study
Biosimilars are biological generics drugs.They undergo a rigorous evaluation to get approved.How to prove biosimilariy from analytical comparability is explained using a recently approved US FDA bio-similar monoclonal antibody.
Generic vs branded medicine
1.Patients have poor or no knowledge of the price variations among branded and generic medicines, and leave the choice of the medicine to the doctor.
2.The government must take up generic promotional schemes, general awareness programs on quality of generics to build confidence among prescribers, pharmacists, and consumers.
New drug approvals & upcoming fda approvals 2021
In the first half of 2021, the U.S. FDA approved a total of 29 innovative drugs, of which 27 were new molecular entities and new biologics approved by the Center for Drug Evaluation and Research (CDER) and the remaining two were Car-T therapies (Abecma and Breyanzi) approved by the Center for Biologics Evaluation and Research (CBER).
Generic drugs and their importance
Generic drugs contain the same active ingredients and are equivalent to their brand name counterparts. They are allowed for sale after the original drug patent expires. Generics are usually cheaper than brands because generic manufacturers don't have the same research and development costs as brand manufacturers. The FDA requires generics to have the same clinical effects as their brand versions.
Bio similar- An opportunities or challenge for Indian Company
1. The global biosimilars market is expected to grow significantly in the coming years due to various drivers such as patent expiries of major biologics and increasing cost containment pressures.
2. Indian companies are well positioned in the biosimilars space due to their established low-cost manufacturing capabilities and expertise in biologics. Key players in India include Dr. Reddy's, Biocon, Cipla and Intas.
3. Developing biosimilars presents several challenges including high development costs, complex clinical trials and unclear regulatory guidelines. Indian companies strategy involves partnerships for cost-effective development and leveraging domestic capabilities and emerging markets for growth.
" GENERIC MEDICINE''
The document discusses generic medicines and their evolution. It notes that generic medicines provide significant economic advantages to consumers and the pharmaceutical industry by decreasing drug prices after brand name patents expire. Approximately 50% of prescriptions in many countries are now filled by lower cost generic drugs. The generic drug market in India, which supplies over 30% of the global generic market, is growing substantially and expected to reach $72 billion by 2020. While generic drugs must demonstrate bioequivalence to the brand name version, they provide significant cost savings over branded drugs for both consumers and healthcare systems.
GSIPA2M, Roundtable 4, Challenging unmerited patents - Sergey Kondratyuk
Patent Oppositions: Improving access to treatment in Ukraine using TRIPS-flexibilities.
Presented by Sergey Kondratyuk, All Ukrainian Netowrk of People Living with HIV.
2004 Prescrire: a drug company (MSD) sues an ISDB member bulletin, and loses...
MSD contro ISDB: Lo strano caso del Dr Donzelli e Mr MSD ha un precedente in Spagna raccontato in questo articolo di PRESCRIRE INTERNATIONAL - JUNE 2004 - VOLUME 13 N° 71- Pag 117
Drug development and discovery in biologics
This document provides an overview of drug development and discovery in biologics. It discusses key topics such as biologics and biosimilars, the integrated discovery and development process of antibodies, the market status and typical manufacturing process of biologics, their therapeutic roles and biological targets in therapy. Some of the challenges in biologics development include the complex manufacturing process, safety implications, immunogenicity, and limited shelf life. Regulations of biologics in India are outlined. Recent FDA-approved biologics are also mentioned. In conclusion, biologics and small molecules are seen as complementary approaches for drug development.
Generic Medication vs Brand name
Nearly 8 in 10 prescriptions filled in the U.S. are for generic drugs. The FDA requires that generic drugs have the same active ingredients, strength, dosage form and administration as the brand name drugs. Generic manufacturers must prove their drugs are bioequivalent to the brand name drugs and meet the same quality standards in manufacturing. On average, generic drugs cost 80-85% less than their brand name counterparts and saved $158 billion in 2010 alone.
Nehemiah 12 commentary
A verse by verse commentary on Nehemiah 12 dealing with the priests and Levites, and then the dedication of the wall in Jerusalem.
INFORMACIÓN DE MOVILIDAD PARA LOS PRÓXIMOS DÍAS
Cabalgata de Reyes Magos de la ciudad y de los distritos Málaga-Este, Bailén-Miraflores, Cruz de Humilladero, Carretera de Cádiz, Churriana, Campanillas y Teatinos-Universidad.
EL BOTÁNICO CIERRA 2016 CON LA PLANTACIÓN DE UN PLÁTANO DE 12 METROS JUNTO A ...
EL BOTÁNICO CIERRA 2016 CON LA PLANTACIÓN DE UN PLÁTANO DE 12 METROS JUNTO A ...Ayuntamiento de Málaga
Con la llegada de este ejemplar se completará la incorporación de otra veintena de árboles de buen porte al jardín histórico, en donde este año se han introducido más de 8.000 plantas de cerca de 50 especies diferentes
Un total de 61 plantas de 12 especies singulares cultivadas en La Concepción han sido distribuidas en 2016 en diferentes parques de Málaga para aumentar su diversidad vegetal.EL PASEO DEL PARQUE Y LA ALAMEDA PERMANECERÁN ABIERTOS AL TRÁFICO CON LA RED...
EL PASEO DEL PARQUE Y LA ALAMEDA PERMANECERÁN ABIERTOS AL TRÁFICO CON LA RED...Ayuntamiento de Málaga
Al espaciarse los horarios, a las 18.30 horas y a las 21.30 horas, la restricción al tráfico privado del Parque y la Alameda no se hará de forma sistemática, sino únicamente cuando resulte estrictamente necesario por razones de seguridad.07a euro book_francestrategie
This document discusses differing economic philosophies between France and Germany that have impacted the Eurozone. It outlines four main points of difference: 1) discretion vs rules, 2) solidarity vs liability, 3) focus on liquidity/contagion vs solvency, and 4) preference for Keynesian stimulus vs austerity/reform. These differences are rooted in each country interpreting its interests through different ideological lenses, with France focused more on commitment and Germany preferring safety valves. The document argues this "Rhine divide" has significant implications for Eurozone crisis management and financial stability.
All About Email Deliverability with Al Iverson
20% of legitimate messages are either blocked or filtered, but delivery and spam reports can be vague and less than helpful. Deliverability expert Al Iverson breaks down industry jargon and demystifies the art of getting to the inbox.
Rebooting the Blue Button
The Blue Button is a way for patients to download their medical information, spearheaded by the VA. As it expands, its original, text-based implementation is a bit long in the tooth. The White House has called on designers to re-imagine the downloadable, printable, consumer-facing health record.
It's intended to be a single-file download, like the healthcare equivalent of your bank statement, for print and screen.
More Related Content
What's hot
Update on U.S. Regulation of Biosimilars
This document summarizes key issues regarding U.S. regulation of biosimilars, including the filing of the first biosimilar applications, requirements for demonstrating interchangeability, state substitution laws, challenges around naming conventions, and arguments on both sides of the naming debate. Industry is pursuing clinical trial designs aimed at demonstrating interchangeability, while FDA guidance is pending and naming remains controversial with pros arguing it ensures traceability and cons arguing it reduces biosimilar uptake.
Biosimilar Drugs: Overview and Regulatory Issues
This document provides an overview of biosimilar drugs and regulatory issues from a presentation given by Phil Johnson. It defines biosimilars and the FDA approval pathways for biologics and biosimilars. The FDA process for demonstrating biosimilarity is described, focusing on analytical, functional, and clinical data requirements. Issues around naming, interchangeability, and state-level legislation regarding substitution are discussed. Finally, the potential financial impact of biosimilars on the healthcare system is noted given rising drug costs and the patent cliff facing many biologic drugs.
Biosimilars-emerging market in india
Hi all, with the rigorous secondary research for almost one month helped me to understand basic things about biosimilars and made me do this presentation. Hope u will appreciate it while going through it. thanks.
If anyone in need of this presentation, pls.put ur emial ID in comment box. will be sharing. and please share your thoughts about the presentation. i will be more thankful.
U.S. Regulation of Biosimilars
Presentation at the Biosimilars and Follow-On Biologics 2014 Americas Conference, sponsored by Paradigm Global Events, February 12, 2014. Presentation focused on:
•Interchangeability
•State Substitution Laws
•Naming
•Risk Evaluation & Mitigation Strategies (REMS) and Their Impact on Biosimilars
•Where FDA Stands on Biosimilars
CHALLENGES TO GENERIC DRUG APPROVALS
Presentation to the IBC 9th Annual Conference on Generic Drugs, September 1999, in Washington, D.C., with an emphasis on reviewing how brand name drug companies have tried to challenge the approval of generic versions of their drug products.
Biosimilar - a mAb case study
Biosimilars are biological generics drugs.They undergo a rigorous evaluation to get approved.How to prove biosimilariy from analytical comparability is explained using a recently approved US FDA bio-similar monoclonal antibody.
Generic vs branded medicine
1.Patients have poor or no knowledge of the price variations among branded and generic medicines, and leave the choice of the medicine to the doctor.
2.The government must take up generic promotional schemes, general awareness programs on quality of generics to build confidence among prescribers, pharmacists, and consumers.
New drug approvals & upcoming fda approvals 2021
In the first half of 2021, the U.S. FDA approved a total of 29 innovative drugs, of which 27 were new molecular entities and new biologics approved by the Center for Drug Evaluation and Research (CDER) and the remaining two were Car-T therapies (Abecma and Breyanzi) approved by the Center for Biologics Evaluation and Research (CBER).
Generic drugs and their importance
Generic drugs contain the same active ingredients and are equivalent to their brand name counterparts. They are allowed for sale after the original drug patent expires. Generics are usually cheaper than brands because generic manufacturers don't have the same research and development costs as brand manufacturers. The FDA requires generics to have the same clinical effects as their brand versions.
Bio similar- An opportunities or challenge for Indian Company
1. The global biosimilars market is expected to grow significantly in the coming years due to various drivers such as patent expiries of major biologics and increasing cost containment pressures.
2. Indian companies are well positioned in the biosimilars space due to their established low-cost manufacturing capabilities and expertise in biologics. Key players in India include Dr. Reddy's, Biocon, Cipla and Intas.
3. Developing biosimilars presents several challenges including high development costs, complex clinical trials and unclear regulatory guidelines. Indian companies strategy involves partnerships for cost-effective development and leveraging domestic capabilities and emerging markets for growth.
" GENERIC MEDICINE''
The document discusses generic medicines and their evolution. It notes that generic medicines provide significant economic advantages to consumers and the pharmaceutical industry by decreasing drug prices after brand name patents expire. Approximately 50% of prescriptions in many countries are now filled by lower cost generic drugs. The generic drug market in India, which supplies over 30% of the global generic market, is growing substantially and expected to reach $72 billion by 2020. While generic drugs must demonstrate bioequivalence to the brand name version, they provide significant cost savings over branded drugs for both consumers and healthcare systems.
GSIPA2M, Roundtable 4, Challenging unmerited patents - Sergey Kondratyuk
Patent Oppositions: Improving access to treatment in Ukraine using TRIPS-flexibilities.
Presented by Sergey Kondratyuk, All Ukrainian Netowrk of People Living with HIV.
2004 Prescrire: a drug company (MSD) sues an ISDB member bulletin, and loses...
MSD contro ISDB: Lo strano caso del Dr Donzelli e Mr MSD ha un precedente in Spagna raccontato in questo articolo di PRESCRIRE INTERNATIONAL - JUNE 2004 - VOLUME 13 N° 71- Pag 117
Drug development and discovery in biologics
This document provides an overview of drug development and discovery in biologics. It discusses key topics such as biologics and biosimilars, the integrated discovery and development process of antibodies, the market status and typical manufacturing process of biologics, their therapeutic roles and biological targets in therapy. Some of the challenges in biologics development include the complex manufacturing process, safety implications, immunogenicity, and limited shelf life. Regulations of biologics in India are outlined. Recent FDA-approved biologics are also mentioned. In conclusion, biologics and small molecules are seen as complementary approaches for drug development.
Generic Medication vs Brand name
Nearly 8 in 10 prescriptions filled in the U.S. are for generic drugs. The FDA requires that generic drugs have the same active ingredients, strength, dosage form and administration as the brand name drugs. Generic manufacturers must prove their drugs are bioequivalent to the brand name drugs and meet the same quality standards in manufacturing. On average, generic drugs cost 80-85% less than their brand name counterparts and saved $158 billion in 2010 alone.
What's hot (15)
New drug approvals & upcoming fda approvals 2021
New drug approvals & upcoming fda approvals 2021
Bio similar- An opportunities or challenge for Indian Company
Bio similar- An opportunities or challenge for Indian Company
GSIPA2M, Roundtable 4, Challenging unmerited patents - Sergey Kondratyuk
GSIPA2M, Roundtable 4, Challenging unmerited patents - Sergey Kondratyuk
2004 Prescrire: a drug company (MSD) sues an ISDB member bulletin, and loses...
2004 Prescrire: a drug company (MSD) sues an ISDB member bulletin, and loses...
Viewers also liked
Nehemiah 12 commentary
A verse by verse commentary on Nehemiah 12 dealing with the priests and Levites, and then the dedication of the wall in Jerusalem.
INFORMACIÓN DE MOVILIDAD PARA LOS PRÓXIMOS DÍAS
Cabalgata de Reyes Magos de la ciudad y de los distritos Málaga-Este, Bailén-Miraflores, Cruz de Humilladero, Carretera de Cádiz, Churriana, Campanillas y Teatinos-Universidad.
EL BOTÁNICO CIERRA 2016 CON LA PLANTACIÓN DE UN PLÁTANO DE 12 METROS JUNTO A ...
EL BOTÁNICO CIERRA 2016 CON LA PLANTACIÓN DE UN PLÁTANO DE 12 METROS JUNTO A ...Ayuntamiento de Málaga
Con la llegada de este ejemplar se completará la incorporación de otra veintena de árboles de buen porte al jardín histórico, en donde este año se han introducido más de 8.000 plantas de cerca de 50 especies diferentes
Un total de 61 plantas de 12 especies singulares cultivadas en La Concepción han sido distribuidas en 2016 en diferentes parques de Málaga para aumentar su diversidad vegetal.EL PASEO DEL PARQUE Y LA ALAMEDA PERMANECERÁN ABIERTOS AL TRÁFICO CON LA RED...
EL PASEO DEL PARQUE Y LA ALAMEDA PERMANECERÁN ABIERTOS AL TRÁFICO CON LA RED...Ayuntamiento de Málaga
Al espaciarse los horarios, a las 18.30 horas y a las 21.30 horas, la restricción al tráfico privado del Parque y la Alameda no se hará de forma sistemática, sino únicamente cuando resulte estrictamente necesario por razones de seguridad.07a euro book_francestrategie
This document discusses differing economic philosophies between France and Germany that have impacted the Eurozone. It outlines four main points of difference: 1) discretion vs rules, 2) solidarity vs liability, 3) focus on liquidity/contagion vs solvency, and 4) preference for Keynesian stimulus vs austerity/reform. These differences are rooted in each country interpreting its interests through different ideological lenses, with France focused more on commitment and Germany preferring safety valves. The document argues this "Rhine divide" has significant implications for Eurozone crisis management and financial stability.
All About Email Deliverability with Al Iverson
20% of legitimate messages are either blocked or filtered, but delivery and spam reports can be vague and less than helpful. Deliverability expert Al Iverson breaks down industry jargon and demystifies the art of getting to the inbox.
Rebooting the Blue Button
The Blue Button is a way for patients to download their medical information, spearheaded by the VA. As it expands, its original, text-based implementation is a bit long in the tooth. The White House has called on designers to re-imagine the downloadable, printable, consumer-facing health record.
It's intended to be a single-file download, like the healthcare equivalent of your bank statement, for print and screen.
Aprendizaje autonomo univim
El documento habla sobre el aprendizaje autónomo. Explica que el aprendizaje es un proceso multifactorial que ocurre dentro y fuera del aula y que involucra experiencias vividas y factores externos. También define el aprendizaje autónomo como un proceso donde el estudiante autorregula su aprendizaje y toma conciencia de sus propios procesos cognitivos y socio-afectivos. Luego, describe las etapas del aprendizaje autónomo: planeación, organización, dirección y control.
In silico methods in drug discovery and development
This document summarizes Stephane Acoca's PhD thesis on in silico methods in drug discovery and development. The thesis describes the development and application of computational drug design methods throughout the drug discovery pipeline. Chapter 2 uses molecular dynamics simulations to study novel Bcl-2 inhibitors Obatoclax and ABT-737 and propose mechanisms of action. Chapter 3 applies virtual screening to identify a novel inhibitor, C35, of Trypanosoma brucei RNA Editing Ligase 1. Chapter 4 develops an algorithm to analyze tandem mass spectrometry data to derive molecular formulas of compounds. Chapter 5 explores using molecular dynamics to generate conformational ensembles of targets for virtual screening. The thesis demonstrates how computational methods can be integrated
How to Design Email Landing Pages That Convert
No matter how great your emails are, you're losing potential customers if you send traffic to landing pages that aren't optimized. A great landing page can make the difference between a successful email marketing campaign and a wasteful one.
In this actionable webinar, you’ll learn the elements of a high-converting landing page, allowing you to deliver delightful campaign experiences.
OpenNebulaConf 2016 - LAB ONE - Vagrant running on OpenNebula? by Florian Heigl
Do you remember Vagrant? It was that last hipster thing before Docker turned into the most recent hipster thing! It's also still really helpful for software evaluations or lab environments. Normally, it works with VirtualBox on your laptop, but this approach can be too limiting. Even running just 10 VMs becomes a stretch on a laptop. It burns through your battery, SSD lifetime, disk space and threatens how many dozen browser tabs you can open... Enter the Vagrant OpenNebula providers! You can actually control Vagrant on your workstation but have the VMs running on your cloud. There are multiple ways to do that, and also limitations. In the workshop, we'll look at what is possible and how you can best benefit from - oh right! - your cloud!
TechDay - Toronto 2016 - Hyperconvergence and OpenNebula
Hyperconvergence integrates compute, storage, networking and virtualization resources from scratch in a commodity hardware box supported by a single vendor. It offers scalability, performance, centralized management, reliability and is software-focused. StorPool is a storage software that can be installed on servers to pool and aggregate the capacity and performance of drives. It provides standard block devices and replicates data across drives and servers for redundancy. StorPool integrates fully with Opennebula to provide a robust hyperconverged infrastructure on commodity hardware using distributed storage.
OpenNebulaConf 2016 - Sunstone integration with FreeIPA using Single Sign by ...
FreeIPA is an integrated Identity and Authentication solution for Linux and Unix environments. It provides a centralized authentication and authorization information and it also stores user data information such as user names, groups, hosts and many different objects to manage the security aspects of a network of computers. FreeIPA uses different technologies, but the core of the authentication system is based on MIT Kerberos technology. Thanks to this technology the authentication works on the basis of tickets to allow users or nodes communicating over a non-secure network to prove their identity to get access to different services. In this talk we will show how it is possible to integrate Sunstone authentication with the FreeIPA SSO thanks to the new Sunstone remote authentication plugin provided by OpenNebula. We will describe how to setup Sunstone in an easy way to include Kerberos authentication using Apache and Phusion Passenger module. This configuration approach also changes the security mechanism used by libvirt to establish the connection between hypervisors. We will explain how it is possible, using the host keytabs generated by FreeIPA, to improve the security between the hypervisors when we have to migrate virtual machines in an insecure network.
Customizing Virtual Machine Images - Javier Fontán
This document discusses various techniques for customizing and optimizing virtual machine images in QCOW2 format. These include mounting images to modify files, using libguestfs and virt-tools, creating CDROMs and scripts for customization, and optimizing images with virt-sparsify to remove unused data and compress images.
Email + Video: What Works, What Doesn't + What to Measure
Experts from Wistia and Litmus teamed up for a webinar focused on how video and email can work together. Kristen Craft, Justine Jordan and Kevin Mandeville discuss:
--The benefits of using video and email together
--How to increase engagement and conversion
--Real examples and tips you can use to get started right away
Tips for Applying Lean Startup in a Large Organization: A Case Study with Tel...
Susana Jurado Apruzzese, an innovator at Telefonica R&D, will outline the main challenges large organizations face when they apply Lean Startup. She’ll share key tips for speeding up the innovation process and doing more with less while staying focused on company strategy, customers, and the market.
35 Quick Fix Home Staging Tips
We’ve rounded up the top 35 BEST bang for your buck quick home staging tips that will ROCK your world. Here are your: 35 Quick Fix Home Staging Tips.
ADW - approche mobile first
Anaïs Vivion nous détaille les avantages à privilégier le support mobile en BtoB et BtoC
Viewers also liked (19)
EL BOTÁNICO CIERRA 2016 CON LA PLANTACIÓN DE UN PLÁTANO DE 12 METROS JUNTO A ...
EL BOTÁNICO CIERRA 2016 CON LA PLANTACIÓN DE UN PLÁTANO DE 12 METROS JUNTO A ...
EL PASEO DEL PARQUE Y LA ALAMEDA PERMANECERÁN ABIERTOS AL TRÁFICO CON LA RED...
EL PASEO DEL PARQUE Y LA ALAMEDA PERMANECERÁN ABIERTOS AL TRÁFICO CON LA RED...
In silico methods in drug discovery and development
In silico methods in drug discovery and development
OpenNebulaConf 2016 - LAB ONE - Vagrant running on OpenNebula? by Florian Heigl
OpenNebulaConf 2016 - LAB ONE - Vagrant running on OpenNebula? by Florian Heigl
TechDay - Toronto 2016 - Hyperconvergence and OpenNebula
TechDay - Toronto 2016 - Hyperconvergence and OpenNebula
OpenNebulaConf 2016 - Sunstone integration with FreeIPA using Single Sign by ...
OpenNebulaConf 2016 - Sunstone integration with FreeIPA using Single Sign by ...
Customizing Virtual Machine Images - Javier Fontán
Customizing Virtual Machine Images - Javier Fontán
Email + Video: What Works, What Doesn't + What to Measure
Email + Video: What Works, What Doesn't + What to Measure
Tips for Applying Lean Startup in a Large Organization: A Case Study with Tel...
Tips for Applying Lean Startup in a Large Organization: A Case Study with Tel...
Similar to In silico Drug Discovery and Development: Benzene Mapping
Role of bioinformatics in drug designing
Role of bioinformatics in different steps of drug discovery and drug designing. Various tools and software used in Computer-aided drug designing.
drug discovery
The document is an assignment on drug discovery and development submitted by Mary Melna to Prof. N.S. Harinarayan. It contains definitions of key terms like drug and the drug discovery and development processes. It then discusses the history of drug discovery from the 1920s onwards and timelines for drug discovery, development and FDA review. The rest of the document outlines various methods of drug discovery like serendipity, screening and molecular design. It also discusses processes like target selection, lead discovery, medicinal chemistry, in vitro and in vivo studies, and clinical trials.
Drug Repurposing in Healthcare Dr. Prerana.pptx
It is a process of identification of new pharmacological indications from old/existing/failed/investigational/already marketed/FDA approved drugs/pro-drugs and the application of the newly developed drugs to the treatment of diseases other than the drug’s original/intended therapeutic use
ICH Guidelines
This document provides an overview of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). It discusses ICH's mission to achieve greater harmonization in drug development and registration. The document then lists and briefly describes the various ICH guidelines related to quality, safety, efficacy, and multidisciplinary topics.
Drug development
The document discusses various aspects of the drug development process including selection of therapeutic targets, approaches to drug discovery, stages of clinical development, and major challenges. Therapeutic needs are determined based on existing therapies, commercial potential, and individualized treatment. Drug discovery approaches include traditional empirical and molecular methods. Clinical development involves phases to test safety, efficacy, and dosing. Major challenges include high costs, regulatory standards, and individualizing treatment.
Drug development
The document discusses various aspects of the drug development process including selection of therapeutic targets, approaches to drug discovery, stages of clinical development, and major challenges. Therapeutic needs are determined based on existing therapies, commercial potential, and individualized treatment. Drug discovery approaches include traditional empirical and molecular methods. Clinical development involves phases to test safety, efficacy, and dosing. Major challenges include high costs, regulatory standards, and individualizing treatment.
Drug Devel Ment
The document discusses various topics related to drug development including:
- Selection of therapeutic targets based on unmet medical needs and commercial potential.
- Approaches to drug discovery including traditional empirical and modern molecular methods.
- Stages of clinical development including pre-clinical and several phases of human trials.
- Major challenges in drug development like high costs, complex regulation, and individualizing treatment.
Drug Design:Discovery, Development and Delivery
The document discusses drug design, development, and delivery. It covers rational drug design using molecular properties and receptor modeling. Computer-assisted drug design uses molecular docking and QSAR methods. Neural networks are also used in drug design. Drug discovery involves identifying candidates and screening for efficacy. Drug development evaluates ADME, toxicity, and safety through preclinical and clinical studies. Drug delivery methods aim to effectively administer pharmaceutical compounds and improve drug release profiles.
Introduction to the drug discovery process
This document discusses the drug discovery process from target identification through FDA approval. It describes methods used for target identification such as genomics, bioinformatics, and proteomics. The stages of lead identification through high-throughput screening and structure-based drug design are outlined. Key aspects of lead optimization like characterizing potency, efficacy, pharmacokinetics, and toxicity are summarized. Details are provided on preclinical and clinical trial phases from Phase 0 through Phase IV post-marketing surveillance. Factors contributing to the declining drug approval rate like increased safety demands are noted. The high costs and failure rates associated with drug development are highlighted.
Drug repurposing
Drug repurposing involves finding new uses for existing drugs to treat different diseases. It provides a more efficient and lower cost alternative to traditional drug development. Computational approaches like network-based, text mining, and semantic methods are used to discover novel drug-disease relationships for drug repurposing. These include identifying modules in biological networks, propagating information across networks, extracting relationships from literature, and constructing semantic networks to predict new associations. Drug repurposing reduces costs and risks compared to de novo drug development.
overview of ich guidelines
The document discusses the International Conference on Harmonization (ICH) and its guidelines. ICH aims to harmonize technical requirements for pharmaceutical registration internationally to ensure safe, effective, and high-quality medicines are developed efficiently. The guidelines are divided into four categories: Quality (Q), Safety (S), Efficacy (E), and Multidisciplinary (M). Some examples of topics covered include stability testing, impurities, clinical trials, good clinical practice, and electronic standards for regulatory information. The overall goal is to increase international cooperation and reduce redundant testing.
Biomarkers and their role in drug discovery and development
A brief introduction to biomarkers with ther history, types and an overview of the journey of biomarker from a hypothesis to a valid established diagnostic parameter.
Drugdiscoveryanddevelopment by khadga raj
The document provides information on various stages of drug discovery and development, including target selection, lead discovery, medicinal chemistry, and clinical trials. It discusses techniques used at each stage such as genomics, proteomics, and bioinformatics for target identification. Key aspects of lead discovery like library development, SAR studies, and high-throughput screening are described. The roles of medicinal chemistry, in vitro and in vivo studies in optimizing leads into drug candidates are also summarized.
Statistics-in-Drug-Development-2015-UC-BS.pptx
The document provides an overview of biostatistics in drug development and clinical trials. It discusses key topics including the drug development process, clinical trial phases, study designs, clinical data types, and case studies. The drug development process involves preclinical research followed by phase 1-4 clinical trials to test drugs for safety and efficacy. Common study designs include parallel group and crossover designs. Biostatisticians are responsible for study design, statistical analysis planning, and interpreting clinical trial results.
Drug discovery and development
The document provides an overview of the drug discovery process. It discusses the various stages involved including target selection, lead discovery, medicinal chemistry, in vitro studies, in vivo studies, and clinical trials.
Target selection involves identifying biological targets implicated in disease through methods like genomics, proteomics, and bioinformatics. Lead discovery focuses on identifying small molecule modulators through synthesis, combinatorial chemistry, assay development, and high-throughput screening. Medicinal chemistry optimizes leads through approaches such as library development, SAR studies, in silico screening, and chemical synthesis. In vitro and in vivo studies evaluate drug candidates prior to clinical trials in humans.
Drug discovery and development
The document discusses the process of drug discovery, including target selection, lead discovery, medicinal chemistry, and clinical trials. Target selection involves identifying cellular or genetic targets involved in disease through techniques like genomics, proteomics, and bioinformatics. Lead discovery focuses on identifying small molecule modulators of protein function through methods like synthesis, combinatorial chemistry, and high-throughput screening. Medicinal chemistry then works to optimize these leads through approaches such as structure-activity relationship studies. Compounds then progress to in vitro and in vivo testing before entering clinical trials.
Drug discovery and development. Introducing
The document discusses the process of drug discovery, including target selection, lead discovery, medicinal chemistry, and clinical trials. Target selection involves identifying cellular or genetic targets involved in disease through techniques like genomics, proteomics, and bioinformatics. Lead discovery focuses on identifying small molecule modulators of protein function through methods like synthesis, combinatorial chemistry, and high-throughput screening. Medicinal chemistry then works to optimize these leads through approaches such as structure-activity relationship studies. Compounds then progress to in vitro and in vivo testing before entering clinical trials.
Drug discovery and development
The document discusses the process of drug discovery, including target selection, lead discovery, medicinal chemistry, in vitro and in vivo studies, and clinical trials. Target selection involves identifying cellular or genetic targets involved in disease through techniques like genomics, proteomics, and bioinformatics. Lead discovery focuses on identifying small molecule modulators of protein function through methods like synthesis, combinatorial chemistry, assay development, and high-throughput screening. Medicinal chemistry then works to optimize these leads. [/SUMMARY]
GVK BIO Informatics ICIC 2013
The document summarizes GVK BIO Informatics, which provides complete informatics solutions from knowledge management to predictive analytics. It highlights key databases and tools developed by GVK including CTOD (Clinical Trial Outcome Database) and a biomarker database. It also describes GVK's knowledge base development through custom data curation for leading database providers and key publications utilizing GVK's GOSTAR database.
ICIC 2013 New Product Introductions GVK Bio Informatics
The document summarizes GVK BIO Informatics, which provides complete informatics solutions from knowledge management to predictive analytics. It highlights key databases and tools developed by GVK including CTOD (Clinical Trial Outcome Database) and biomarker databases containing clinical trial data, small molecules, and biomarkers. The document also discusses GVK's knowledge base development through custom data curation for database providers and lists many publications that have utilized GVK's GOSTAR database.
Similar to In silico Drug Discovery and Development: Benzene Mapping (20)
Biomarkers and their role in drug discovery and development
Biomarkers and their role in drug discovery and development
ICIC 2013 New Product Introductions GVK Bio Informatics
ICIC 2013 New Product Introductions GVK Bio Informatics
More from josearzon99
Synthesis of electrospun cellulose fibers corrected
This document summarizes a study that synthesized cellulose acetate fiber membranes through electrospinning for use in protein separation. The methodology involved preparing cellulose acetate solutions of varying concentrations, electrospinning the solutions while varying parameters like voltage and humidity, and analyzing the resulting fiber properties through SEM and FTIR. The objectives were to synthesize and analyze the cellulose acetate fibers, remove acetyl groups to produce cellulose fibers, and control electrospinning parameters to vary pore size for potential protein separation applications. SEM images showed fibers produced from different cellulose acetate concentrations, and future work will measure fiber properties and test protein separation performance.
Reflective essay biomedical techniques
José A. Cruz-Arzón reflects on his experience in the Biomedical Techniques class as part of the RISE Research Program. He discusses several workshops and research experiences that helped him grow as a scientist. The "From DNA to protein" workshop taught him DNA extraction, proteomics, SDS-PAGE, and how proteins can be affected by disease. His research on isolating and characterizing mycobacteriophages provided a complete research experience. Another project on electrospinning nanofibers helped lead to a research assistant position. Overall, the class developed his skills and values as a scientist through various workshops, seminars, and research opportunities.
Lab summariesassignment 2 done
This document contains summaries of three laboratory assignments:
1) The first summary discusses how nanotechnology is used in biomedicine, including using nanoparticles and hydroxyapatite fibers to help regenerate cells and avoid implant corrosion. Electron microscopy is used to study the fibers.
2) The second summary explains how plasminogen activator was isolated from HeLa broth using magnetic affinity nanoparticles, chromatography to measure absorbance, and electrophoresis to analyze protein isolation.
3) The third summary describes an in silico approach to study protein-protein interactions and drug design. The workshop involved identifying a protein target, analyzing interactions, mapping ligand sizes, and analyzing benzene molecule binding and clustering to the target.
Final Mycrobacteriophages Article
Two novel mycobacteriophages, dubbed Mikriplithari and Ususindagari, were isolated from a soil sample in Puerto Rico. The soil sample was enriched with Mycobacterium smegmatis to amplify any phages present. Two distinct phage populations were purified through plaque purification and titrated, with Mikriplithari having a titer of 6.00 × 108 pfu/mL and Ususindagari having a titer of 2.60 × 108 pfu/mL. The isolated phages show potential for novel genotypes and phenotypes that could be useful in biomedical applications due to increasing antibiotic resistance.
Electrospinning Technique Final Report
This study investigated the effect of rotational and translational target movement on electrospun nanofibers. Polyethylene oxide (PEO) stock solution was used to create non-aligned nanofibers via electrospinning. The fibers were then metalized with palladium using sputtering to form shells. The shells were analyzed using scanning electron microscopy and were found to form successfully. Rotational and translational movement of the target during electrospinning was found to produce more uniform fibers.
Final electrospinning technique report
This document discusses the use of electrospinning to produce aligned and non-aligned poly(ethylene oxide) (PEO) nanofibers, which are then metallized with palladium via sputtering. The palladium forms shells on the nanofibers that can be used for gas sensing applications. Rotational and translational movement of the collector during electrospinning produces more uniform and organized aligned fibers compared to static-collector non-aligned fibers. The fibers are then calcined to evaporate the templates and leave behind the palladium shells for further characterization.
Electrospinning Technique on PEO Nanofibers
This document discusses a study on the effects of a rotating and translating target on the alignment of electrospun nanofibers. The study aimed to determine if using a rotational and translational target during electrospinning would produce more uniformly aligned fibers compared to non-aligned electrospinning. The procedure involved electrospinning nanofibers with and without target rotation/translation. The fibers were then characterized and analyzed to evaluate if rotational electrospinning better aligned the fibers. Future work is proposed to calcine the fibers to isolate palladium shells deposited on them during sputtering, and later determine the fibers' potential for sensor applications.
Curriculum vitae
This document is a resume for Jose A. Cruz-Arzon. It summarizes his education, courses, research experience, publications, languages, and memberships. He is currently studying biology at the University of Puerto Rico at Cayey and expects to graduate in 2012. His research experience includes isolating mycobacteriophages from Puerto Rican soils and studying the effect of rotational targets on electrospun nanofibers. He has authored two articles on his research that were presented to the RISE program in 2013. In addition to Spanish, he speaks English fluently.
Revolutionary discovery (creative writing)
Dr. José Cruz Arzón and his assistant Charlene Rivera are called to Brazil to investigate people in a poor community who are experiencing hallucinations, delusions, and other neurological symptoms. After failing to find a cause through conventional tests, Dr. Cruz decides to use his experimental shrinking ray and Neuromobile 10nm vehicle to shrink himself and Rivera and travel through a patient's bloodstream to examine their brain directly. There, they discover low levels of the dysbindin-1 protein, which they had been studying. Cruz and Rivera theorize this could be causing genetic mutations from environmental factors, and name the condition "schizophrenia," from the Greek for "split mind." They may have discovered the biological basis
Creative writing rise 2013 (practice)
1) Dr. José Cruz Arzón discovered a strange new plant species while doing field work in Puerto Rico in the year 2120.
2) The plant had unusual red coloring and thick stem and leaves composed of cartilage instead of hard bone. It also had the ability to move itself.
3) Through laboratory analysis and further observation, Dr. Arzón determined the plant had evolved the ability to move to escape pollution and capture more carbon dioxide through specialized tissues.
4) He named the plant "Sperare mundis," meaning "hope of the world," as a message that nature is adapting to the damage humans have caused, and there is still time to fix the environment.
Experience at general biology i laboratory
The document summarizes the experiences and experiments conducted in a general biology I laboratory course. It covers topics like detecting macromolecules like carbohydrates, proteins, and starch in various substances using tests like Benedict's test, Biuret test, and Lugol's test. It also describes experiments on transport across a cell membrane and enzyme activity at different substrate concentrations. Further topics explored include photosynthesis, cellular respiration, molecular genetics involving agarose gel electrophoresis, DNA extraction, and Mendelian genetics using corn and PTC paper.
Mycobacteriophages presentation
This document contains environmental data from a sample collected on March 4th 2013 at 6:15 AM in a rural area at coordinates 18.17336, -65.86055. The temperature was 25°C, depth was 2.5 cm, and soil was dry. It also describes enrichment and streaking protocols carried out on March 5th and 11th 2013 and two rounds of plaque purification on April 3rd and 4th 2013. Preliminary results found two successful rounds of purification with a third planned and positive soil samples seeming to come from areas with dark soil and high plant density.
First revision lab summaries #1
1. The document provides instructions for laboratory writing assignments as part of the RISE Program at the University of Puerto Rico in Cayey. Students are to write 8-10 sentence summaries of 160-170 words for each assignment and submit them to their professor using a specific template and process.
2. A rubric is provided to grade the summaries based on purpose and objectives of the lab techniques, biological competence, English competence, and critical thinking.
3. A sample template is given for Assignment 1 that includes spaces for the student name, date, summary, and word count. The summary is to reference the criteria in the grading rubric.
More from josearzon99 (13)
Synthesis of electrospun cellulose fibers corrected
Synthesis of electrospun cellulose fibers corrected
Recently uploaded
How are Lilac French Bulldogs Beauty Charming the World and Capturing Hearts....
“After being the most listed dog breed in the United States for 31
years in a row, the Labrador Retriever has dropped to second place
in the American Kennel Club's annual survey of the country's most
popular canines. The French Bulldog is the new top dog in the
United States as of 2022. The stylish puppy has ascended the
rankings in rapid time despite having health concerns and limited
color choices.”
NIMA2024 | De toegevoegde waarde van DEI en ESG in campagnes | Nathalie Lam |...
Nathalie zal delen hoe DEI en ESG een fundamentele rol kunnen spelen in je merkstrategie en je de juiste aansluiting kan creëren met je doelgroep. Door middel van voorbeelden en simpele handvatten toont ze hoe dit in jouw organisatie toegepast kan worden.
❼❷⓿❺❻❷❽❷❼❽ Dpboss Matka Result Satta Matka Guessing Satta Fix jodi Kalyan Fin...
❼❷⓿❺❻❷❽❷❼❽ Dpboss Matka Result Satta Matka Guessing Satta Fix jodi Kalyan Fin...❼❷⓿❺❻❷❽❷❼❽ Dpboss Kalyan Satta Matka Guessing Matka Result Main Bazar chart
❼❷⓿❺❻❷❽❷❼❽ Dpboss Matka Result Satta Matka Guessing Satta Fix jodi Kalyan Final ank Satta Matka Dpbos Final ank Satta Matta Matka 143 Kalyan Matka Guessing Final Matka Final ank Today Matka 420 Satta Batta Satta 143 Kalyan Chart Main Bazar Chart vip Matka Guessing Dpboss 143 Guessing Kalyan night Best Forex Brokers Comparison in INDIA 2024
Navigating the world of forex trading can be challenging, especially for beginners. To help you make an informed decision, we have comprehensively compared the best forex brokers in India for 2024. This article, reviewed by Top Forex Brokers Review, will cover featured award winners, the best forex brokers, featured offers, the best copy trading platforms, the best forex brokers for beginners, the best MetaTrader brokers, and recently updated reviews. We will focus on FP Markets, Black Bull, EightCap, IC Markets, and Octa.
一比一原版(QMUE毕业证书)英国爱丁堡玛格丽特女王大学毕业证文凭如何办理
永久可查学历认证【微信：A575476】【(QMUE毕业证书)英国爱丁堡玛格丽特女王大学毕业证成绩单Offer】【微信：A575476】（留信学历认证永久存档查询）采用学校原版纸张、特殊工艺完全按照原版一比一制作（包括：隐形水印，阴影底纹，钢印LOGO烫金烫银，LOGO烫金烫银复合重叠，文字图案浮雕，激光镭射，紫外荧光，温感，复印防伪）行业标杆！精益求精，诚心合作，真诚制作！多年品质 ,按需精细制作，24小时接单,全套进口原装设备，十五年致力于帮助留学生解决难题，业务范围有加拿大、英国、澳洲、韩国、美国、新加坡，新西兰等学历材料，包您满意。
【业务选择办理准则】
一、工作未确定，回国需先给父母、亲戚朋友看下文凭的情况，办理一份就读学校的毕业证【微信：A575476】文凭即可
二、回国进私企、外企、自己做生意的情况，这些单位是不查询毕业证真伪的，而且国内没有渠道去查询国外文凭的真假，也不需要提供真实教育部认证。鉴于此，办理一份毕业证【微信：A575476】即可
三、进国企，银行，事业单位，考公务员等等，这些单位是必需要提供真实教育部认证的，办理教育部认证所需资料众多且烦琐，所有材料您都必须提供原件，我们凭借丰富的经验，快捷的绿色通道帮您快速整合材料，让您少走弯路。
留信网认证的作用:
1:该专业认证可证明留学生真实身份
2:同时对留学生所学专业登记给予评定
3:国家专业人才认证中心颁发入库证书
4:这个认证书并且可以归档倒地方
5:凡事获得留信网入网的信息将会逐步更新到个人身份内，将在公安局网内查询个人身份证信息后，同步读取人才网入库信息
6:个人职称评审加20分
7:个人信誉贷款加10分
8:在国家人才网主办的国家网络招聘大会中纳入资料，供国家高端企业选择人才
→ 【关于价格问题（保证一手价格）
我们所定的价格是非常合理的，而且我们现在做得单子大多数都是代理和回头客户介绍的所以一般现在有新的单子 我给客户的都是第一手的代理价格，因为我想坦诚对待大家 不想跟大家在价格方面浪费时间
对于老客户或者被老客户介绍过来的朋友，我们都会适当给一些优惠。
选择实体注册公司办理，更放心，更安全！我们的承诺：可来公司面谈，可签订合同，会陪同客户一起到教育部认证窗口递交认证材料，客户在教育部官方认证查询网站查询到认证通过结果后付款，不成功不收费！
The Most Inspiring Entrepreneurs to Follow in 2024.pdf
In a world where the potential of youth innovation remains vastly untouched, there emerges a guiding light in the form of Norm Goldstein, the Founder and CEO of EduNetwork Partners. His dedication to this cause has earned him recognition as a Congressional Leadership Award recipient.
Best Competitive Marble Pricing in Dubai - ☎ 9928909666
Stone Art Hub offers the best competitive Marble Pricing in Dubai, ensuring affordability without compromising quality. With a wide range of exquisite marble options to choose from, you can enhance your spaces with elegance and sophistication. For inquiries or orders, contact us at ☎ 9928909666. Experience luxury at unbeatable prices.
Dpboss Matka Guessing Satta Matta Matka Kalyan Chart Indian Matka
Dpboss Matka Guessing Satta Matta Matka Kalyan Chart Indian Matka➒➌➎➏➑➐➋➑➐➐Dpboss Matka Guessing Satta Matka Kalyan Chart Indian Matka
9356872877Sattamatka.satta.matka.satta matka.kalyan weekly chart.kalyan chart.kalyan jodi chart.kalyan penal chart.kalyan today.kalyan open.fix satta.fix fix fix Satta matka nambar.一比一原版新西兰奥塔哥大学毕业证（otago毕业证）如何办理
一模一样【微信：A575476】【新西兰奥塔哥大学毕业证（otago毕业证）成绩单Offer】【微信：A575476】（留信学历认证永久存档查询）采用学校原版纸张、特殊工艺完全按照原版一比一制作（包括：隐形水印，阴影底纹，钢印LOGO烫金烫银，LOGO烫金烫银复合重叠，文字图案浮雕，激光镭射，紫外荧光，温感，复印防伪）行业标杆！精益求精，诚心合作，真诚制作！多年品质 ,按需精细制作，24小时接单,全套进口原装设备，十五年致力于帮助留学生解决难题，业务范围有加拿大、英国、澳洲、韩国、美国、新加坡，新西兰等学历材料，包您满意。
【业务选择办理准则】
一、工作未确定，回国需先给父母、亲戚朋友看下文凭的情况，办理一份就读学校的毕业证【微信：A575476】文凭即可
二、回国进私企、外企、自己做生意的情况，这些单位是不查询毕业证真伪的，而且国内没有渠道去查询国外文凭的真假，也不需要提供真实教育部认证。鉴于此，办理一份毕业证【微信：A575476】即可
三、进国企，银行，事业单位，考公务员等等，这些单位是必需要提供真实教育部认证的，办理教育部认证所需资料众多且烦琐，所有材料您都必须提供原件，我们凭借丰富的经验，快捷的绿色通道帮您快速整合材料，让您少走弯路。
留信网认证的作用:
1:该专业认证可证明留学生真实身份
2:同时对留学生所学专业登记给予评定
3:国家专业人才认证中心颁发入库证书
4:这个认证书并且可以归档倒地方
5:凡事获得留信网入网的信息将会逐步更新到个人身份内，将在公安局网内查询个人身份证信息后，同步读取人才网入库信息
6:个人职称评审加20分
7:个人信誉贷款加10分
8:在国家人才网主办的国家网络招聘大会中纳入资料，供国家高端企业选择人才
→ 【关于价格问题（保证一手价格）
我们所定的价格是非常合理的，而且我们现在做得单子大多数都是代理和回头客户介绍的所以一般现在有新的单子 我给客户的都是第一手的代理价格，因为我想坦诚对待大家 不想跟大家在价格方面浪费时间
对于老客户或者被老客户介绍过来的朋友，我们都会适当给一些优惠。
选择实体注册公司办理，更放心，更安全！我们的承诺：可来公司面谈，可签订合同，会陪同客户一起到教育部认证窗口递交认证材料，客户在教育部官方认证查询网站查询到认证通过结果后付款，不成功不收费！
Part 2 Deep Dive: Navigating the 2024 Slowdown
Introduction
The global retail industry has weathered numerous storms, with the financial crisis of 2008 serving as a poignant reminder of the sector's resilience and adaptability. However, as we navigate the complex landscape of 2024, retailers face a unique set of challenges that demand innovative strategies and a fundamental shift in mindset. This white paper contrasts the impact of the 2008 recession on the retail sector with the current headwinds retailers are grappling with, while offering a comprehensive roadmap for success in this new paradigm.
Cover Story - China's Investment Leader - Dr. Alyce SU
In World Expo 2010 Shanghai – the most visited Expo in the World History
https://www.britannica.com/event/Expo-Shanghai-2010
China’s official organizer of the Expo, CCPIT (China Council for the Promotion of International Trade https://en.ccpit.org/) has chosen Dr. Alyce Su as the Cover Person with Cover Story, in the Expo’s official magazine distributed throughout the Expo, showcasing China’s New Generation of Leaders to the World.
2024-6-01-IMPACTSilver-Corp-Presentation.pdf
IMPACT Silver is a pure silver zinc producer with over $260 million in revenue since 2008 and a large 100% owned 210km Mexico land package - 2024 catalysts includes new 14% grade zinc Plomosas mine and 20,000m of fully funded exploration drilling.
The Genesis of BriansClub.cm Famous Dark WEb Platform
BriansClub.cm, a famous platform on the dark web, has become one of the most infamous carding marketplaces, specializing in the sale of stolen credit card data.
Digital Transformation Frameworks: Driving Digital Excellence
[To download this presentation, visit:
https://www.oeconsulting.com.sg/training-presentations]
This presentation is a curated compilation of PowerPoint diagrams and templates designed to illustrate 20 different digital transformation frameworks and models. These frameworks are based on recent industry trends and best practices, ensuring that the content remains relevant and up-to-date.
Key highlights include Microsoft's Digital Transformation Framework, which focuses on driving innovation and efficiency, and McKinsey's Ten Guiding Principles, which provide strategic insights for successful digital transformation. Additionally, Forrester's framework emphasizes enhancing customer experiences and modernizing IT infrastructure, while IDC's MaturityScape helps assess and develop organizational digital maturity. MIT's framework explores cutting-edge strategies for achieving digital success.
These materials are perfect for enhancing your business or classroom presentations, offering visual aids to supplement your insights. Please note that while comprehensive, these slides are intended as supplementary resources and may not be complete for standalone instructional purposes.
Frameworks/Models included:
Microsoft’s Digital Transformation Framework
McKinsey’s Ten Guiding Principles of Digital Transformation
Forrester’s Digital Transformation Framework
IDC’s Digital Transformation MaturityScape
MIT’s Digital Transformation Framework
Gartner’s Digital Transformation Framework
Accenture’s Digital Strategy & Enterprise Frameworks
Deloitte’s Digital Industrial Transformation Framework
Capgemini’s Digital Transformation Framework
PwC’s Digital Transformation Framework
Cisco’s Digital Transformation Framework
Cognizant’s Digital Transformation Framework
DXC Technology’s Digital Transformation Framework
The BCG Strategy Palette
McKinsey’s Digital Transformation Framework
Digital Transformation Compass
Four Levels of Digital Maturity
Design Thinking Framework
Business Model Canvas
Customer Journey Map
The latest Heat Pump Manual from Newentide
𝐔𝐧𝐯𝐞𝐢𝐥 𝐭𝐡𝐞 𝐅𝐮𝐭𝐮𝐫𝐞 𝐨𝐟 𝐄𝐧𝐞𝐫𝐠𝐲 𝐄𝐟𝐟𝐢𝐜𝐢𝐞𝐧𝐜𝐲 𝐰𝐢𝐭𝐡 𝐍𝐄𝐖𝐍𝐓𝐈𝐃𝐄’𝐬 𝐋𝐚𝐭𝐞𝐬𝐭 𝐎𝐟𝐟𝐞𝐫𝐢𝐧𝐠𝐬
Explore the details in our newly released product manual, which showcases NEWNTIDE's advanced heat pump technologies. Delve into our energy-efficient and eco-friendly solutions tailored for diverse global markets.
Business storytelling: key ingredients to a story
Storytelling is an incredibly valuable tool to share data and information. To get the most impact from stories there are a number of key ingredients. These are based on science and human nature. Using these elements in a story you can deliver information impactfully, ensure action and drive change.
Unveiling the Dynamic Personalities, Key Dates, and Horoscope Insights: Gemin...
Explore the fascinating world of the Gemini Zodiac Sign. Discover the unique personality traits, key dates, and horoscope insights of Gemini individuals. Learn how their sociable, communicative nature and boundless curiosity make them the dynamic explorers of the zodiac. Dive into the duality of the Gemini sign and understand their intellectual and adventurous spirit.
Innovative Uses of Revit in Urban Planning and Design
Discover innovative uses of Revit in urban planning and design, enhancing city landscapes with advanced architectural solutions. Understand how architectural firms are using Revit to transform how processes and outcomes within urban planning and design fields look. They are supplementing work and putting in value through speed and imagination that the architects and planners are placing into composing progressive urban areas that are not only colorful but also pragmatic.
Recently uploaded (20)
How are Lilac French Bulldogs Beauty Charming the World and Capturing Hearts....
How are Lilac French Bulldogs Beauty Charming the World and Capturing Hearts....
NIMA2024 | De toegevoegde waarde van DEI en ESG in campagnes | Nathalie Lam |...
NIMA2024 | De toegevoegde waarde van DEI en ESG in campagnes | Nathalie Lam |...
❼❷⓿❺❻❷❽❷❼❽ Dpboss Matka Result Satta Matka Guessing Satta Fix jodi Kalyan Fin...
❼❷⓿❺❻❷❽❷❼❽ Dpboss Matka Result Satta Matka Guessing Satta Fix jodi Kalyan Fin...
The Most Inspiring Entrepreneurs to Follow in 2024.pdf
The Most Inspiring Entrepreneurs to Follow in 2024.pdf
Best Competitive Marble Pricing in Dubai - ☎ 9928909666
Best Competitive Marble Pricing in Dubai - ☎ 9928909666
Dpboss Matka Guessing Satta Matta Matka Kalyan Chart Indian Matka
Dpboss Matka Guessing Satta Matta Matka Kalyan Chart Indian Matka
Cover Story - China's Investment Leader - Dr. Alyce SU
Cover Story - China's Investment Leader - Dr. Alyce SU
The Genesis of BriansClub.cm Famous Dark WEb Platform
The Genesis of BriansClub.cm Famous Dark WEb Platform
Digital Transformation Frameworks: Driving Digital Excellence
Digital Transformation Frameworks: Driving Digital Excellence
Unveiling the Dynamic Personalities, Key Dates, and Horoscope Insights: Gemin...
Unveiling the Dynamic Personalities, Key Dates, and Horoscope Insights: Gemin...
Innovative Uses of Revit in Urban Planning and Design
Innovative Uses of Revit in Urban Planning and Design
In silico Drug Discovery and Development: Benzene Mapping
- 1. IN SILICO DRUG DISCOVERY AND DEVELOPMENT GROUP A: Edwin J. Alvarado José Antonio Cruz-Arzón Crystal K. Colón Carla Jeanine Figueroa-García MENTOR: Jessica Díaz
- 2. INTRODUCTION Structure-based Drug Design Pharmacophore Models FTMap: Benzene Probes
- 3. OBJECTIVE Identification of Optimal Targets for Drug Development: Benzene Mapping
- 4. Target Analysis Primary Sequence Analysis Optimal Targets For Drug Development Chemical Probe Screening Therapeutically Relevant Protein Targets Biomedically Relevant Biological Problem Drug Discovery Strategy
- 5. RECEPTOR / TARGET PREPARATION Download RECEPTOR / TARGET file CODE: 1BVE NAME: HIV-1 Protease
- 6. RECEPTOR / TARGET PREPARATION Analyze using PyMOL® software Separate PROTEIN from LIGAND HIV-1 P. DMP
- 8. BENZENE MAPPING AND ANALYSIS Benzene probe mapping Loading results onto model
- 9. Benzene configuration analysis Binding propensity comparison BENZENE MAPPING AND ANALYSIS
- 10. Benzene cluster selection CLUSTER I: 001 CLUSTER II: 013 CLUSTER III: 022 CLUSTER IV: 028 BENZENE MAPPING AND ANALYSIS
- 11. BENZENE MAPPING AND ANALYSIS CLUSTERS Benzene Map HIV-1 P.
- 12. CONCLUSION Pharmacophore model can be derived. Then on, potential drugs can be developed.
Editor's Notes
- Crystal Edwin Jose Carla
- Carla
- Edwin